Integration of Automated Insulin Delivery System with a Long-Term Continuous Glucose Monitoring System by Sequel Med Tech and Senseonics
In a groundbreaking move, Sequel Med Tech and Senseonics Holdings have announced their intention to integrate Sequel's twiist Automated Insulin Delivery System with Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system. This integration is expected to launch in the third quarter (Q3) of 2025, marking a significant step forward in diabetes care.
The twiist pump by Sequel Med Tech is designed to work with multiple CGMs, including Senseonics' implantable Eversense 365, which lasts a full year in the body before replacement. This partnership is part of a larger movement towards greater interoperability in diabetes management technology, providing users with more customizable options when combining pumps and CGMs.
The integrated system will be the first Automated Insulin Delivery (AID) system compatible with the Senseonics Eversense 365, the world's first and only one-year CGM system. This collaboration is expected to offer people with type 1 diabetes more tools for managing their diabetes, potentially leading to improved glucose control, increased convenience, and greater flexibility.
Sequel's CEO, Alan Lotvin, stated that the partnership with Senseonics is an investment in innovations that empower people with diabetes with options in managing their diabetes. Senseonics' CEO, Tim Goodnow, echoed this sentiment, stating that the collaboration marks a significant step forward in transforming diabetes care.
Meanwhile, the Simplera Sync sensor for MiniMed 780G has received FDA approval, and the MiniMed 780G system for diabetes has received CE Mark. These developments indicate a growing trend towards advancements in diabetes technology.
In addition to this partnership, Sequel remains committed to advancing diabetes technology and expanding partnerships to give people with diabetes more choice and flexibility in how they manage their diabetes. Another notable collaboration is the one between PharmaSens and SiBionics, aiming to advance the development of an all-in-one patch pump.
This integration between Sequel's twiist and Senseonics' Eversense 365 is expected to offer greater personalization and more choice for people living with diabetes. People living with type 1 diabetes who choose to use twiist will have the flexibility to select from two compatible CGM partners, the Senseonics Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor.
The launch of this integrated system is anticipated soon after the public announcements about the compatibility surfaced around July 2025. Both companies are united by a shared commitment to simplifying diabetes management and improving quality of life for those living with the condition.
Science and health-and-wellness are intertwined in the diabetes care industry, as companies such as Sequel Med Tech and Senseonics Holdings collaborate to develop innovative technologies. The integrated twiist Automated Insulin Delivery System and Eversense 365 Continuous Glucose Monitoring (CGM) system, due to launch in Q3 2025, promises medical-conditions management improvements for people with type 1 diabetes, potentially leading to better glucose control, increased convenience, and greater flexibility.
